Multiple Sclerosis

[vc_row][vc_column][vc_column_text]

Multiple Sclerosis

Sativex for the management of multiple sclerosis symptoms (PubMed)

THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis (PubMed)

Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity (PubMed)

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors (PubMed)

Oromucosal delta9-tetrahydrocannabinol/cannabidiol for neuropathic pain associated with multiple sclerosis: An uncontrolled, open-label, 2-year extension trial(PubMed)

Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis(PubMed)

Sativex long-term use: An open-label trial in patients with spasticity due to multiple sclerosis(PubMed)

A double-blind, randomized, placebo-controlled, parallel-group study of Sativex, in subjects with symptoms of spasticity due to multiple sclerosis (PubMed)

Meta-analysis of cannabis based treatments for neuropathic and multiple sclerosis-related pain(PubMed)

Sativex: Clinical efficacy and tolerability in the treatment of symptoms of multiple sclerosis and neuropathic pain (PubMed)

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex®), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis (European Journal of Neurology)

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: A role for A2A receptors(ScienceDirect)

Cannabinoid Modulation of Neuroinflammatory Disorders (Current Neuropharmacology)

Cannabinoids and multiple sclerosis (Pharmacology and Therapeutics)

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial (The Lancet)

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up (J Neurol Neurosurg Psychiatry)

Cannabinoids in the management of spasticity associated with multiple sclerosis (Neuropsychiatric Disease and Treatment)

Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study (Multiple Sclerosis Journal)

Interaction Between The Protective Effects Of Cannabidiol And Palmitoylethanolamide In Experimental Model Of Multiple Sclerosis In C57BL/6 Mice (Neuroscience)

The Endocannabinoid System Is Dysregulated in Multiple Sclerosis and in Experimental Autoimmune Encephalomyelitis (MedScape)

Whole plant cannabis extracts in the treatment of spasticity in multiple sclerosis: a systematic review (BioMed Central)

[/vc_column_text][/vc_column][/vc_row]